US 12,168,646 B2
Aryl hydrocarbon receptor agonists and uses thereof
Tom Yao-Hsiang Wu, San Diego, CA (US); and Qihui Jin, San Diego, CA (US)
Assigned to NEXYS THERAPEUTICS, INC., San Francisco, CA (US)
Filed by NEXYS THERAPEUTICS, INC., San Diego, CA (US)
Filed on Feb. 5, 2024, as Appl. No. 18/433,237.
Application 18/433,237 is a continuation of application No. PCT/US2023/012166, filed on Feb. 2, 2023.
Claims priority of provisional application 63/306,458, filed on Feb. 3, 2022.
Prior Publication US 2024/0208913 A1, Jun. 27, 2024
Int. Cl. C07D 239/42 (2006.01); A61K 31/505 (2006.01); A61K 31/655 (2006.01); A61K 31/675 (2006.01); C07F 9/6512 (2006.01)
CPC C07D 239/42 (2013.01) [A61K 31/505 (2013.01); A61K 31/655 (2013.01); A61K 31/675 (2013.01); C07F 9/6512 (2013.01)] 21 Claims
 
1. A compound of Formula (IA):

OG Complex Work Unit Chemistry
wherein:
R3 is selected from H, CN, halo, C1-4 alkyl, C1-4 haloalkyl, and C1-4 haloalkoxy;
each R1 is independently selected from —OR, COOR, C1-4 haloalkyl, C1-4 haloalkoxy, CN, —PO3R2, —SO2R, —SO3R, halo, and C1-4 alkyl optionally substituted with one or two groups selected from —OR′, COOR′, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 haloalkyl, —CN, and —NR′2;
each R is independently selected from H, C1-4 haloalkyl, and C1-4 alkyl optionally substituted with one or two groups selected from —OR′, COOR′, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 haloalkyl, —CN, and —NR′2;
each R′ is independently selected from H and C1-3 alkyl;
m is selected from 0, 1 and 2; and
or a pharmaceutically acceptable salt thereof.